We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-1.96%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$114M
AUM Growth
-$29.8M
Cap. Flow
-$27M
Cap. Flow %
-23.68%
Top 10 Hldgs %
42.25%
Holding
85
New
11
Increased
13
Reduced
16
Closed
19

Top Buys

Rank Stock Value
1
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$4.51M
2
IBB icon
iShares Biotechnology ETF
IBB
+$2.38M
3
BPMC
Blueprint Medicines
BPMC
+$2.19M
4
CDTX
Cidara Therapeutics
CDTX
+$1.66M
5
ADXS
Advaxis Inc
ADXS
+$1.57M

Top Sells

Rank Stock Value
1
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$15M
2
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$9.26M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.15M
4
BSTC
BioSpecifics Technologies Corp.
BSTC
+$1.81M
5
TSRO
TESARO, Inc.
TSRO
+$1.77M

Sector Composition

Rank Sector Weight
1 Healthcare 81.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCRX icon
51
BioCryst Pharmaceuticals
BCRX
$2.42B
$417K 0.37%
+65,900
New +$343K
ABEO icon
52
Abeona Therapeutics
ABEO
$355M
$372K 0.33%
+3,072
New +$481K
PVLA
53
Palvella Therapeutics
PVLA
$2.05B
$314K 0.28%
2,792
– –
EPIX
54
DELISTED
ESSA Pharma
EPIX
$289K 0.25%
4,902
-4,873
-50% -$212K
NEOS
55
DELISTED
Neos Therapeutics, Inc
NEOS
$227K 0.2%
38,873
– –
CYAD
56
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$222K 0.2%
12,528
– –
FSTX
57
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$219K 0.19%
+6,853
New +$251K
SGYP
58
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$207K 0.18%
34,000
-240,563
-88% -$1.26M
AVGR
59
DELISTED
Avinger, Inc. Common Stock
AVGR
– –
0
– –
GNVC
60
DELISTED
GenVec, Inc.
GNVC
$31K 0.03%
9,580
– –
TMBR
61
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$29K 0.03%
+5
New +$25.6K
CHEKW
62
DELISTED
Check-Cap Ltd. Series A Warrant
CHEKW
$10K 0.01%
15,250
-35,968
-70% -$25.5K
CVM icon
63
CEL-SCI Corp
CVM
$19.9M
– –
-170
Closed -$39K
GYRE icon
64
Gyre Therapeutics
GYRE
$629M
– –
-630
Closed -$86K
NERV icon
65
Minerva Neurosciences
NERV
$191M
– –
-4,138
Closed -$467K
NGNE icon
66
Neurogene
NGNE
$672M
– –
-1,000
Closed -$267K
PTN
67
Palatin Technologies
PTN
$14.4M
– –
-206
Closed -$162K
RGLS
68
DELISTED
Regulus Therapeutics
RGLS
– –
-3,513
Closed -$1.39M
RIGL icon
69
Rigel Pharmaceuticals
RIGL
$723M
– –
-34,000
Closed -$1.25M
ALPN
70
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-3,750
Closed -$122K
ISEE
71
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-46,600
Closed -$2.15M
DRNA
72
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-119,300
Closed -$701K
BSTC
73
DELISTED
BioSpecifics Technologies Corp.
BSTC
– –
-39,704
Closed -$1.81M
ARRY
74
DELISTED
Array Biopharma Inc
ARRY
– –
-69,300
Closed -$468K
DXTR
75
DELISTED
Dextera Surgical Inc.
DXTR
– –
-140,275
Closed -$264K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, DAFNA Capital Management held 85 positions worth $114M, down 21% from $144M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

DAFNA Capital Management withdrew a net $27M in Q4 2016, closing 19 positions and reducing 16 holdings. Its most notable exit was VITAE PHARMACEUTICALS INC COMMON STOCK, an estimated $15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 68% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Viracta Therapeutics, Inc. Common Stock worth $4.1M.

  • DAFNA Capital Management's largest Q4 2016 buy was Viracta Therapeutics, Inc. Common Stock: 32,388 shares worth $4.1M.
  • DAFNA Capital Management added most to Alder Biopharmaceuticals in Q4 2016, an estimated $1.45M increase.
  • DAFNA Capital Management's biggest Q4 2016 reduction was TESARO, Inc., cutting an estimated $1.77M.
  • DAFNA Capital Management fully exited VITAE PHARMACEUTICALS INC COMMON STOCK in Q4 2016, selling an estimated $15M.
  • DAFNA Capital Management's ten largest holdings make up 42% of its $114M portfolio in Q4 2016.
  • DAFNA Capital Management opened 11 new positions and closed 19 in Q4 2016.
  • DAFNA Capital Management's portfolio value fell 21% quarter-over-quarter to $114M.

Based on DAFNA Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.